The joint use of 99m Tc-MAA-SPECT/CT and cone-beam CT optimizes radioembolization planning
Macarena Rodríguez-Fraile 1 , Ana Ezponda 2 , Fabiana Grisanti 3 , Verónica Morán 4 , Marta Calvo 2 , Pablo Berián 2 , Antonio Martínez de la Cuesta 2 , Lidia Sancho 5 , Mercedes Iñarrairaegui 6 , Bruno Sangro 6 , José Ignacio Bilbao 2
Purpose: To determine which imaging method used during radioembolization (RE) work-up: contrast-enhanced computed tomography (CECT), 99mTc-MAA-SPECT/CT or cone beam-CT (CBCT), more accurately predicts the final target volume (TgV) as well as the influence that each modality has in the dosimetric calculation.
Methods: TgVs from 99mTc-MAA-SPECT/CT, CECT and CBCT were consecutively obtained in 24 patients treated with RE and compared with 90Y PET/CT TgV. Using the TgVs estimated by each imaging modality and a fictitious activity of 1 GBq, the corresponding absorbed doses by tumor and non-tumoral parenchyma were calculated for each patient. The absorbed doses for each modality were compared with the ones obtained using 90Y PET/CT TgV.
Results: 99mTc-MAA-SPECT/CT predicted 90Y PET/CT TgV better than CBCT or CECT, even for selective or superselective administrations. Likewise, 99mTc-MAA-SPECT/CT showed dosimetric values more similar to those obtained with 90Y PET/CT. Nevertheless, CBCT provided essential information for RE planning, such as ensuring the total coverage of the tumor and, in cases with more than one feeding artery, splitting the activity according to the volume of tumor perfused by each artery.
Conclusion: The joint use of 99mTc-MAA-SPECT/CT and CBCT optimizes dosimetric planning for RE procedures, enabling a more accurate personalized approach.
CITATION EJNMMI Res. 2021 Mar 4;11(1):23. doi: 10.1186/s13550-021-00764-z